Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial on the Safety and Feasibility of Neoadjuvant Low Dose Radiation, Chemotherapy and Durvalumab for Potentially Resectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT05157542 is registered in ClinicalTrials.gov with Juan LI, MD as lead sponsor.

NCT NCT05157542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05157542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial on the Safety and Feasibility of Neoadjuvant Low Dose Radiation, Chemotherapy and Durvalumab for Potentially Resectable Stage III Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Juan LI, MD
Phase
Phase 1
Overall status
Unknown status
Start date
June 10, 2021
Completion date
June 10, 2023
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii non-small cell lung cancer